Chemistry Holdings Inc.
Chemistry Holdings Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Chemistry Holdings Inc..
Chemistry Holdings Inc. is a company.
Key people at Chemistry Holdings Inc..
Key people at Chemistry Holdings Inc..
Chemistry Holdings Inc. is a formulation technology company specializing in innovative delivery systems for nutraceutical, pharmaceutical, food, beverage, nutrition, wellness, and social impact industries. It develops biopolymer technologies for liquid encapsulation, microencapsulation of dry powders, nanoemulsions, microemulsions, microcapsules, chewable pods, and taste-masking solutions to enhance active ingredient stability, solubility, and delivery in various forms like chewable products with customizable shapes, colors, and flavors[1][3][4][5]. The company serves consumer goods sectors by partnering with communities in food, beverage, nutrition, and social impact, employing 1-10 people including encapsulation scientists, product designers, market strategists, and project specialists to create sustainable, disruptive products[2][3]. In 2019, it agreed to an all-stock acquisition by CURE Pharmaceutical to expand oral drug delivery platforms, though completion details post-April 2019 are unavailable in sources[1][4][6].
Chemistry Holdings was founded around 2015 in Santa Monica, California, at 2917 Santa Monica Blvd, focusing on intellectual property in bioscience, chemistry, product creation, encapsulation, and delivery systems[3][5]. Key figure Joshua Held highlighted the company's formulation technologies, noting their fit with CURE Pharmaceutical's oral thin film expertise during the 2019 acquisition announcement[4]. The idea emerged from pioneering biopolymer tech for nutraceutical and pharmaceutical applications, evolving to target broader industries like food, beverage, wellness, and social impact, with early emphasis on sustainable materials for scalable, beneficial products[2][3][4]. Pivotal moment: The April 1, 2019, agreement to merge with CURE, aiming to accelerate drug delivery innovations amid market growth[1][4].
Chemistry Holdings rides the wave of advanced drug and nutraceutical delivery innovations, addressing challenges in active ingredient stability, solubility, and patient-friendly formats amid growing demand for oral thin films, chewables, and microencapsulation[1][4]. Timing aligned with the booming drug delivery market in 2019, fueled by needs for better efficacy, safety, and wellness experiences in pharmaceuticals and consumer goods[1][4]. Market forces like rising nutraceutical adoption, sustainable biotech, and personalized medicine favor its tech, influencing ecosystems by enabling versatile platforms that expand beyond traditional pills to pods and films[2][3][5]. The CURE acquisition positioned it to transform patient outcomes, accelerating treatments via combined expertise[1][4][6].
Post-2019 acquisition intent, Chemistry Holdings likely integrated into CURE's vertically integrated drug delivery operations, enhancing platforms for nutraceuticals and pharma with sustained focus on encapsulation breakthroughs[1][4]. Next steps may involve scaling chewable and microcapsule tech amid trends like personalized wellness, sustainable biotech, and AI-optimized formulations. Its influence could evolve by powering accessible, high-impact products in growing markets, redefining delivery to inspire broader adoption in health and nutrition ecosystems—echoing its core mission as an innovative partner[2][3][4].
